Alkoxyalkyl S-prenylthiosalicylates for treatment of cancer
View Patent ↗Disclosed are alkoxyalkyl S-prenylthiosalicylates and pharmaceutical compositions containing the same and a pharmaceutically acceptable carrier. Methods for treating a human afflicted with cancer, including solid tumors, or a hematological malignancy by administering to the human in need thereof an effective amount of an alkoxyalkyl S-prenylthiosalicylate are also disclosed.
1. A compound of the formula:
wherein
Pren is farnesyl or geranylgeranyl;
X is H, F, or Cl;
R is H, or alkyl; and
Z is alkyl.
2. The compound of claim 1 , which is methoxymethyl S-farnesylthiosalicylate (FTS-MOMS).
3. The compound of claim 1 , which is methoxymethyl S-geranylgeranylthiosalicylate.
4. The compound of claim 1 , which is methoxymethyl 5-fluoro-S-farnesylthiosalicylate.
5. The compound of claim 1 , which is ethoxymethyl S-farnesylthiosalicylate.
6. A method of treating a human afflicted with cancer, comprising administering to the human in need thereof an effective amount of a compound having the formula:
wherein
Pren is farnesyl or geranylgeranyl;
X is H, F, or Cl;
R is H, or alkyl; and
Z is alkyl.
7. The method of claim 6 , wherein the human is administered methoxymethyl S-farnesylthiosalicylate (FTS-MOMS).
8. The method of claim 6 , wherein the human is administered methoxymethyl S-geranylgeranylthiosalicylate.
9. The method of claim 6 , wherein the human is administered methoxymethyl 5-fluoro-S-farnesylthiosalicylate.
10. The method of claim 6 , wherein the human is administered ethoxymethyl S-farnesylthiosalicylate.
11. The method of claim 6 , wherein the cancer is a solid tumor.
12. The method of claim 11 , wherein the solid tumor is a pancreatic tumor.
13. The method of claim 11 , wherein the solid tumor is a lung tumor.
14. The method of claim 11 , wherein the solid tumor is a colon cancer.
15. The method of claim 11 , wherein the solid tumor is a glioblastoma.
16. The method of claim 11 , wherein the solid tumor is a brain metastasis of a primary tumor.
17. The method of claim 11 , wherein the solid tumor is a breast tumor.
18. The method of claim 11 , wherein the solid tumor is an ovarian tumor.
19. The method of claim 11 , wherein the solid tumor is a prostate tumor.
20. The method of claim 11 , wherein the solid tumor is a melanoma.
21. The method of claim 6 , wherein the cancer is a hematological malignancy.
22. The method of claim 21 , wherein the hematological malignancy is myelodysplastic syndrome.
23. The method of claim 21 , wherein the hematological malignancy is acute myeloid leukemia (AML).
24. A pharmaceutical composition comprising an effective amount of the compound of the formula:
wherein
Pren is farnesyl or geranylgeranyl;
X is H, F, or Cl;
R is H, or alkyl; and
Z is alkyl; and
a pharmaceutically acceptable carrier.
25. The composition of claim 24 , which is in the form of a soft gelatin capsule.
26. The composition of claim 24 , which is methoxymethyl S-farnesylthiosalicylate; and which is in the form of a soft gelatin capsule.